The Effect of Systematic Endurance Training in Treatment of Women With Lipedema
Launched by NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY · Aug 15, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called LipidEx, is studying the effects of high-intensity interval training (HIIT) on women with lipedema, a condition that causes an abnormal buildup of fat, mostly in the legs, and can lead to pain and difficulties in daily life. The trial aims to find out if this type of exercise can help reduce pain and improve the quality of life for women living with lipedema. Over 12 weeks, participants will alternate between doing HIIT and receiving standard care to see how their condition changes.
To participate in this trial, women need to have a confirmed diagnosis of lipedema and should not have ongoing eating disorders or any orthopedic issues that could prevent them from exercising. If eligible, participants can expect to engage in a structured exercise program and have their pain levels, body fat, and overall well-being assessed throughout the study. This trial is not yet recruiting, but it represents a promising step toward finding better treatment options for those affected by lipedema.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Confirmed lipedema diagnosis
- Exclusion Criteria:
- • Ongoing eating disorders and/or orthopedic limitations for exercise training
About Norwegian University Of Science And Technology
The Norwegian University of Science and Technology (NTNU) is a leading research institution dedicated to advancing knowledge and innovation in various scientific fields. Renowned for its commitment to interdisciplinary collaboration, NTNU plays a pivotal role in addressing global health challenges through rigorous clinical trials and research initiatives. The university's emphasis on cutting-edge technology and its strong partnerships with healthcare sectors position it as a key player in translational research, ensuring that findings contribute effectively to improving public health and patient care. With a focus on ethical standards and scientific integrity, NTNU is dedicated to fostering advancements that enhance the quality of life and health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Trondheim, , Norway
Patients applied
Trial Officials
Øivind Rognmo
Study Director
Norwegian University of Science and Technology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported